NasVax Ltd. (TASE: NSVX) has obtained Polish Ministry of Health approval for a Phase IIa clinical trial of its Type C hepatitis vaccine at the Bydgoszcz military hospital. The trial will evaluate the efficacy and safety of the anti-CD3 oral vaccine.
Trial will include a group that will receive a placebo. The trial will evaluate various dosages of the vaccine on various immunology measurements. In March, NasVax reported successful results of the vaccine in a Phase IIa clinical trial trial in Israel on patients with non- Alcoholic Steatohepatitis (NASH) liver disease.
No comments:
Post a Comment